These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 29391566)
41. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372 [TBL] [Abstract][Full Text] [Related]
42. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Jayaraman M; Ansell SM; Mui BL; Tam YK; Chen J; Du X; Butler D; Eltepu L; Matsuda S; Narayanannair JK; Rajeev KG; Hafez IM; Akinc A; Maier MA; Tracy MA; Cullis PR; Madden TD; Manoharan M; Hope MJ Angew Chem Int Ed Engl; 2012 Aug; 51(34):8529-33. PubMed ID: 22782619 [TBL] [Abstract][Full Text] [Related]
43. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells. Uemura Y; Naoi T; Kanai Y; Kobayashi K Pharm Dev Technol; 2019 Mar; 24(3):263-268. PubMed ID: 29688101 [TBL] [Abstract][Full Text] [Related]
44. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Alabi CA; Love KT; Sahay G; Yin H; Luly KM; Langer R; Anderson DG Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12881-6. PubMed ID: 23882076 [TBL] [Abstract][Full Text] [Related]
45. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery. Li H; Chen M; Su Z; Sun M; Ping Q Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421 [TBL] [Abstract][Full Text] [Related]
46. Lipid nanoparticles for hepatic delivery of small interfering RNA. Yu B; Hsu SH; Zhou C; Wang X; Terp MC; Wu Y; Teng L; Mao Y; Wang F; Xue W; Jacob ST; Ghoshal K; Lee RJ; Lee LJ Biomaterials; 2012 Sep; 33(25):5924-34. PubMed ID: 22652024 [TBL] [Abstract][Full Text] [Related]
47. Lipid-based nanoparticles in the systemic delivery of siRNA. Lin Q; Chen J; Zhang Z; Zheng G Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813 [TBL] [Abstract][Full Text] [Related]
49. siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo. Suzuki Y; Hyodo K; Tanaka Y; Ishihara H J Control Release; 2015 Dec; 220(Pt A):44-50. PubMed ID: 26478014 [TBL] [Abstract][Full Text] [Related]
50. Galactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo. Park HJ; Jeon EJ; Lee JS; Hong SH; Cho AN; Lee J; Moon JS; Jung KE; Oh JW; Lee H; Cho SW Adv Healthc Mater; 2016 Nov; 5(22):2931-2941. PubMed ID: 27774775 [TBL] [Abstract][Full Text] [Related]
51. An investigation of nano- and micron-sized carriers based on calcium carbonate and polylactic acid for oral administration of siRNA. Akhmetova DR; Rogova A; Tishchenko YA; Mitusova KA; Postovalova AS; Dovbysh OV; Gavrilova NV; Epifanovskaya OS; Pyatiizbyantsev TA; Shakirova AI; Brodskaia AV; Shipilovskikh SA; Timin AS Expert Opin Drug Deliv; 2024 Aug; 21(8):1279-1295. PubMed ID: 39141571 [TBL] [Abstract][Full Text] [Related]
52. Biodistribution and metabolism studies of lipid nanoparticle-formulated internally [3H]-labeled siRNA in mice. Christensen J; Litherland K; Faller T; van de Kerkhof E; Natt F; Hunziker J; Boos J; Beuvink I; Bowman K; Baryza J; Beverly M; Vargeese C; Heudi O; Stoeckli M; Krauser J; Swart P Drug Metab Dispos; 2014 Mar; 42(3):431-40. PubMed ID: 24389421 [TBL] [Abstract][Full Text] [Related]
53. Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation. Kubota K; Onishi K; Sawaki K; Li T; Mitsuoka K; Sato T; Takeoka S Int J Nanomedicine; 2017; 12():5121-5133. PubMed ID: 28790820 [TBL] [Abstract][Full Text] [Related]
54. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates. Suzuki Y; Hyodo K; Suzuki T; Tanaka Y; Kikuchi H; Ishihara H Int J Pharm; 2017 Mar; 519(1-2):34-43. PubMed ID: 28089936 [TBL] [Abstract][Full Text] [Related]
55. Oral siRNA Delivery to Treat Colorectal Liver Metastases. Kang SH; Revuri V; Lee SJ; Cho S; Park IK; Cho KJ; Bae WK; Lee YK ACS Nano; 2017 Oct; 11(10):10417-10429. PubMed ID: 28902489 [TBL] [Abstract][Full Text] [Related]
57. Lipid-based nanocarriers for the oral administration of biopharmaceutics. Karamanidou T; Bourganis V; Kammona O; Kiparissides C Nanomedicine (Lond); 2016 Nov; 11(22):3009-3032. PubMed ID: 27781558 [TBL] [Abstract][Full Text] [Related]
58. Nanotechnology for in vivo targeted siRNA delivery. Dahlman JE; Kauffman KJ; Langer R; Anderson DG Adv Genet; 2014; 88():37-69. PubMed ID: 25409603 [TBL] [Abstract][Full Text] [Related]
59. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery. Neves AR; Queiroz JF; Costa Lima SA; Figueiredo F; Fernandes R; Reis S J Colloid Interface Sci; 2016 Feb; 463():258-65. PubMed ID: 26550783 [TBL] [Abstract][Full Text] [Related]
60. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. Prakash TP; Lima WF; Murray HM; Elbashir S; Cantley W; Foster D; Jayaraman M; Chappell AE; Manoharan M; Swayze EE; Crooke ST ACS Chem Biol; 2013 Jul; 8(7):1402-6. PubMed ID: 23614580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]